Drug Profile
MK 0608
Latest Information Update: 30 Jan 2008
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 12 Dec 2006 Phase-I clinical trials in Hepatitis C in USA (unspecified route)
- 24 Oct 2006 Preclinical trials in Hepatitis C infections in USA (unspecified route)